According to the company, the climate-controlled facility enables pharmaceutical, biotechnology and nutraceutical clients access to their full range of analytical services which include formulation development, quality control, quality assurance and regulatory affairs.
Fred Sancilio, CEO and chief scientist of Sancilio & Company, said: “The new, fully cGMP-compliant combined operation is FDA registered, and licensed for DEA Schedule two, three and four. The key attributes of both the manufacturing facility and the laboratory are rapid turnaround and competitive pricing.”
Nealie Newberger, vice president of laboratory services of Sancilio & Company, said: “We anticipate that the addition of small batch contract manufacturing to our roster of services strategically positions the company as a full-service pharmaceutical and nutritional enterprise.”